Amgen (BSP:AMGN34) Cyclically Adjusted FCF per Share: R$0.00 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BSP:AMGN34 Amgen Inc BSP:AMGN34
89 GF Score
Price R$70.80
GF Value R$64.34
Valuation Fairly Valued
! 8 Warning Signs
View Full Analysis

What is Amgen Cyclically Adjusted FCF per Share?

Amgen BSP:AMGN34 +2.80% 89 Cyclically Adjusted FCF per Share is R$0.00 as of Jun. 2026. GuruFocus rates BSP:AMGN34 with a GF Score™ of 89/100 and a GF Value™ of R$64.34 (Fairly Valued). The stock has 8 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Amgen's adjusted free cash flow per share for the three months ended in Jun. 2026 was R$1.174. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is R$0.00 for the trailing ten years ended in Jun. 2026.

During the past 12 months, Amgen's average Cyclically Adjusted FCF Growth Rate was 2.60% per year. During the past 3 years, the average Cyclically Adjusted FCF Growth Rate was 4.70% per year. During the past 5 years, the average Cyclically Adjusted FCF Growth Rate was 8.00% per year. During the past 10 years, the average Cyclically Adjusted FCF Growth Rate was 10.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted FCF Growth Rate of Amgen was 25.30% per year. The lowest was 4.70% per year. And the median was 15.20% per year.

As of today (2026-08-05), Amgen's current stock price is R$70.80. Amgen's Cyclically Adjusted FCF per Share for the quarter that ended in Jun. 2026 was R$0.00. Amgen's Cyclically Adjusted Price-to-FCF of today is .

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of Amgen was 24.24. The lowest was 13.20. And the median was 18.59.


Amgen  (BSP:AMGN34) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of Amgen was 24.24. The lowest was 13.20. And the median was 18.59.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Amgen Cyclically Adjusted FCF per Share Related Terms


Amgen Cyclically Adjusted FCF per Share Historical Data

* Premium members only.

The historical data trend for Amgen's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Amgen Cyclically Adjusted FCF per Share Chart

Amgen Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.82 3.01 2.88 3.88 3.63

Amgen Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.44 3.36 3.63 3.38 0.00

BSP:AMGN34 vs GILD, PFE, BMY: Cyclically Adjusted FCF per Share Comparison

For the Drug Manufacturers - General subindustry, Amgen's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Amgen Cyclically Adjusted Price-to-FCF vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Amgen's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Amgen's Cyclically Adjusted Price-to-FCF falls into.


BSP:AMGN34
89GF Score
Amgen Inc BSP:AMGN34
Cyclically Adjusted FCF per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Amgen Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Amgen's adjusted Free Cash Flow per Share data for the three months ended in Jun. 2026 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=1.174/333.9520*333.9520
=1.174

Current CPI (Jun. 2026) = 333.9520.

Amgen Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201609 0.400 241.428 0.553
201612 0.464 241.432 0.642
201703 0.334 243.801 0.458
201706 0.341 244.955 0.465
201709 0.503 246.819 0.681
201712 0.463 246.524 0.627
201803 0.424 249.554 0.567
201806 0.391 251.989 0.518
201809 0.701 252.439 0.927
201812 0.642 251.233 0.853
201903 0.379 254.202 0.498
201906 0.287 256.143 0.374
201909 0.784 256.759 1.020
201912 0.571 256.974 0.742
202003 0.585 258.115 0.757
202006 0.840 257.797 1.088
202009 1.059 260.280 1.359
202012 0.623 260.474 0.799
202103 0.671 264.877 0.846
202106 0.544 271.696 0.669
202109 0.720 274.310 0.877
202112 0.903 278.802 1.082
202203 0.637 287.504 0.740
202206 0.565 296.311 0.637
202209 0.981 296.808 1.104
202212 0.804 296.797 0.905
202303 0.249 301.836 0.275
202306 1.239 305.109 1.356
202309 0.824 307.789 0.894
202312 0.094 306.746 0.102
202403 0.152 312.332 0.163
202406 0.790 314.175 0.840
202409 1.209 315.301 1.281
202412 1.772 315.605 1.875
202503 0.373 319.799 0.390
202506 0.700 322.561 0.725
202509 1.501 324.800 1.543
202512 0.345 324.054 0.356
202603 0.507 330.213 0.513
202606 1.174 333.952 1.174

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

What does a Cyclically Adjusted FCF per Share of R$0.00 mean?
Amgen (BSP:AMGN34) has a Cyclically Adjusted FCF per Share of R$0.00 as of Jun. 2026. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Amgen and its competitors.
Is Amgen's Cyclically Adjusted FCF per Share too high?
Amgen's current Cyclically Adjusted FCF per Share is R$0.00. Overall, Amgen has a GF Score™ of 89/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Amgen's Cyclically Adjusted FCF per Share compare to GILD and PFE?
Amgen's Cyclically Adjusted FCF per Share of R$0.00 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted FCF per Share for a Drug Manufacturers company?
A good Cyclically Adjusted FCF per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted FCF per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted FCF per Share mean?
A high Cyclically Adjusted FCF per Share can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Amgen and its competitors. Amgen's current Cyclically Adjusted FCF per Share is R$0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Amgen stock overvalued right now?
Based on GuruFocus' analysis, Amgen (BSP:AMGN34) is currently considered Fairly Valued. The stock's GF Value™ is R$64.34, compared to a current price of R$70.80 — trading 10% above its estimated fair value. The current Cyclically Adjusted FCF per Share is R$0.00. Amgen's overall GF Score™ is 89/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted FCF per Share calculated?
Cyclically Adjusted FCF per Share is calculated from a company's financial statements. For Amgen (BSP:AMGN34), the current Cyclically Adjusted FCF per Share is R$0.00 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Amgen (BSP:AMGN34) Overvalued in 2026?

Based on GuruFocus' analysis, Amgen stock appears to be overvalued. The current stock price of R$70.80 is trading 10% above its estimated GF Value™ of R$64.34. GuruFocus considers Amgen to be Fairly Valued.

Key valuation signals for BSP:AMGN34:

  • Cyclically Adjusted FCF per Share: R$0.00
  • GF Value™: R$64.34 vs. price of R$70.80 (10% above fair value)
  • GF Score™: 89/100 with 8 warning signs

No single metric tells the full story. See the BSP:AMGN34 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Amgen Business Description

Address One Amgen Center Drive, Thousand Oaks, CA, USA, 91320-1799
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
89GF Score

Get the complete analysis for BSP:AMGN34

Cyclically Adjusted FCF per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

R$70.80
Price
R$64.34
GF Value